Summary
The pharmacokinetics of a single intravenous dose of diazepam 0.1 mg/kg was studied in 6 healthy volunteers, in random order under controlled conditions and following pretreatment with its major metabolite, desmethyldiazepam (20 mg/day) for one week. In the two subjects with the highest plasma concentration of desmethyldiazepam (990 and 1100 ng/ml, respectively), total plasma clearance (Cl) of diazepam was reduced after desmethyldiazepam, by 31% and 54%, respectively. In three individuals there was a moderate decrease of 14% to 21%, and no effect was seen in one volunteer. Cl was significantly reduced (11.5±1.8 vs. 9.1±3.3 ml/min;p=0.015) and elimination half-life tended to be prolonged (38.5±10.4 vs. 65.8±67.1 h;p=0.15). It is concluded that high concentrations of desmethyldiazepam can influence the elimination of its parent drug diazepam by product inhibition.
This is a preview of subscription content, log in via an institution to check access.
References
Schwartz MA, Koechlin BA, Postma E, Palmer S, Krol G (1965) Metabolism of diazepam in rat, dog and man. J Pharmacol Exp Ther 149: 423–435
Klotz U, Antonin KH, Bieck PR (1976) Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol 10: 121–126
Rutherford DM, Okoko A, Tyrer PJ (1978) Plasma concentrations of diazepam and desmethyldiazepam during chronic diazepam therapy. Br J Clin Pharmacol 6: 69–73
Greenblatt DJ, Laughren TP, Allen MD, Harmatz JS, Shader RI (1981) Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol 1: 35–40
van der Kleijn E, van Rossum JM, Muskens ETJM, Rijntjes NVM (1971) Pharmacokinetics of diazepam in dogs, mice and humans. Acta Pharmacol Toxicol 29 (Suppl 3): 109–127
Kaplan SA, Jack ML, Alexander K, Weinfield RE (1973) Pharmacokinetic profile of diazepam following single intravenous and oral and chronic oral administration. J Pharm Sci 62: 1789–1796
Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55: 347–359
Klotz U, Antonin KH, Bieck PR (1976) Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 199: 67–73
Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfield RE, Ronfeld R, Weissmann L, Moore JD, Gibaldi M, Kaplan SA (1977) Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5: 481–494
Berman M, Weiss MF (1974) SAAM Manual, Laboratory of Theoretical Biology, National Institute of Health, Bethesda Maryland
Riegelman S, Loo JCK, Rowland M (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit the properties of a single compartment. J Pharm Sci 57: 117–123
Jusko WJ, Gibaldi M (1972) Effects of change in elimination on various parameters of the two-compartment open model. J Pharm Sci 61: 1270–1273
von Bahr C (1970) Binding to cytochrome P-450 and metabolism of desmethylimipramine and metabolites in rat liver microsomes. Acta Pharmacol Toxicol 28 (Suppl 1): 13
Jähnchen E, Levy G (1972) Inhibition of phenylbutazone elimination by its metabolite oxyphenbutazone. Proc Soc Exp Biol Med 141: 963–965
Soda DM, Levy G (1975) Inhibition of drug metabolism by hydroxylated metabolites: Cross-inhibition and specificity. J Pharm Sci 64: 1928–1931
Bast A, Noordhoek J (1981) Product inhibition during hepatic microsomal N-demethylation of aminopyrine in the rat. Biochem Pharmacol 30: 19–24
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klotz, U., Reimann, I. Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam. Eur J Clin Pharmacol 21, 161–163 (1981). https://doi.org/10.1007/BF00637518
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637518